News

While early use of high-efficacy treatments lowers relapse rates among patients with relapsing-remitting multiple sclerosis (MS) compared to lower-efficacy ones, starting these therapies earlier may only impact the accumulation of disability among young patients, according to data presented at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. Earlier treatment…

Ozanimod (RPC1063) was seen to lower relapse rates and reduce brain and spinal cord lesions among patients with relapsing multiple sclerosis (MS) participating in a Phase 3 study of the treatment. Giancarlo Comi, from the Vita-Salute San Raffaele University, in Italy, announced the results in a presentation during the ongoing…

This is a special edition of Multiple Sclerosis News Today's daily Alexa Flash Briefing, covering the latest news from the 7th Joint ECTRIMS-ACTRIMS Meeting currently underway in Paris, France. The MS News today team in on-site at the conference, providing exclusive coverage of the presentations and speakers.

People with multiple sclerosis (MS) who quit smoking have better health outcomes than those who continue. Therefore, MS-related costs can be reduced by encouraging smokers to quit. Similar results were observed in MS patients with healthy vitamin D levels, Maura Pugliatti, from the University of Ferrara, in Italy, said Friday in a presentation at the…

Long-term exposure of at least three years of beta-interferon therapies such as Rebif or Avonex may increase the survival of multiple sclerosis (MS) patients, a population-based study suggests. The study reporting the findings, titled “Beta-interferon and mortality in multiple sclerosis: a population-based international study,” was presented Friday at the ongoing ECTRIMS-ACTRIMS Meeting…

After the first round of symptoms, multiple sclerosis can stay mild without causing major problems for decades, a 30-year British study indicates. Karen K. Chung of the University College London Institute of Neurology discussed the findings at the ECTRIMS-ACTRIMS meeting in Paris, which started Oct. 25 and runs until 28. His presentation was titled “Does…

Sanofi Genzyme’s multiple sclerosis therapy Aubagio (teriflunomide) does not appear to cause birth defects in humans as it does in laboratory animals, researchers concluded after studying more than 100 pregnant women with MS. Their research indicated that birth-defect findings in rats and rabbits do not translate to humans. The team presented its…

A strong immune reaction to an Epstein-Barr virus infection and low levels of vitamin D appear to increase the risk of multiple sclerosis (MS) independent of each other, said researchers in a presentation at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. Previous studies have shown that serum antibody titers…

Babies born to women who are treated with Tysabri (natalizumab) during pregnancy are more likely to develop abnormal blood cell counts if the treatment continues beyond week 30 of pregnancy. Since more relapses occurred in women who quit the treatment before this time, researchers from the Ludwig Maximilian University…

Older patients with secondary progressive multiple sclerosis (SPMS) have reduced risk of experiencing disease relapse, according to a study presented at the 7th Joint ECTRIMS-ACTRIMS Meeting, being held Oct. 25-28, in Paris, France. The study, “Relapses in patients with secondary progressive MS: a matter of disease duration…

Genentech’s Ocrevus (ocrelizumab) improved the vision of people with relapsing multiple sclerosis better than the widely used therapy interferon beta-1a, according to clinical trial findings presented at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris. Dr. Laura Balcer of the department of neurology at New York University made the presentation, titled “Effect…

Personalized medicine is the future of multiple sclerosis treatment, and research now taking place to collect and analyze data and pinpoint biomarkers will help make possible approaches that — one day — will put MS into “complete remission” patient by patient, said Richard Rudick, vice president of Development Sciences at…

Inhibiting a protein found at high levels in immune cells located in the brain can rejuvenate myelin, the protective coating around nerve cells, according to a multiple sclerosis study in mice. Blocking the protein, known as the colony-stimulating factor 1 receptor, or CSF1R, can also prevent the immune cells from…

Radiologically isolated syndrome (RIS) is a rare and relatively recent condition in which people have multiple sclerosis (MS)-like brain and spinal cord lesions without showing disease activity. But since the establishment of the RIS diagnosis, researchers have not reached an agreement on whether these patients should receive MS disease-modifying therapies.

Mavenclad (cladribine tablets), an oral therapy by Merck that’s approved to treat people with active relapsing multiple sclerosis in much of Europe, is a “smart therapy” that is showing real and long-term benefit after a short treatment course, said Gavin Giovannoni, chair of neurology at Barts and The London School of Medicine…

While Tysabri (natalizumab) failed to slow worsening disability in people with secondary progressive multiple sclerosis (SPMS) in a Phase 3 trial, researchers now suggest that the treatment did improve walking and arm function in people with advanced disability. Researchers presented new analyses of data from the ASCEND trial (…

MD1003, a high-dose biotin developed by MedDay, slowed or prevented further disease progression among progressive multiple sclerosis (MS) patients in a Phase 3 clinical trial, researchers announced at the Oct. 25–28 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. The effects of the treatment were seen to be upheld over…

Novartis’ Siponimod led to a dramatic drop in the number of inflammation patches in the brains and spinal cords of secondary progressive multiple sclerosis patients, according to a Phase 3 clinical trial. Robert Fox of the Cleveland Clinic’s Mellen Center for Treatment and Research in Multiple Sclerosis presented the findings…

Sanofi Genzyme‘s Lemtrada (alemtuzumab) and Biogen’s Tysabri (natalizumab) are more effective in preventing conversion to secondary progressive multiple sclerosis (SPMS) compared to older injectable drugs, researchers from the University of Cambridge in the U.K. reported at the 7th Joint ECTRIMS-ACTRIMS Meeting Oct. 25-28 in Paris. The…

Using strategies to promote intellectual enrichment among patients with pediatric-onset multiple sclerosis could be essential to achieving better cognitive, social, and professional performances during adult life, according to researchers at the University of Florence in Italy. The finding was the subject of an oral presentation titled, “Cognitive reserve is…

A University of British Columbia study found a link between depression and increased disability in women with multiple sclerosis. Dr. Kyla McKay said the study of more than 1,200 patients found no link between anxiety or bipolar disorder and increased disability, however. She presented the findings at the 7th Joint ECTRIMS-ACTRIMS Meeting in…

The types of brain and spinal cord inflammation patches that occur in a precursor condition to multiple sclerosis help determine whether a person develops MS in the next 15 years, a British neurologist reported today. Wallace J. Brownlee of the University College London Institute of Neurology made the observation in…

Propionic acid supplements alter the composition and behavior of immune cells in multiple sclerosis (MS) patients — likely by changing the composition of gut bacteria, according to Alexander Duscha from Ruhr University Bochum in Bochum, Germany. The finding, presented Wednesday at the 7th Joint ECTRIMS-ACTRIMS Meeting running in Paris…

People with a demyelinating disease associated with antibodies against a myelin oligodendrocyte glycoprotein (MOG), most often develop episodes of optic neuritis (inflammation of the optic nerve) that can be treated with corticosteroids, according to data presented today at the 7th Joint ECTRIMS-ACTRIMS Meeting from Oct. 25-28 in Paris. MOG antibody-associated demyelination is a…

The numbers of people being diagnosed with multiple sclerosis is rising worldwide, though distinct differences in factors thought to drive this rise are evident among regions, according to MS data represented by researchers on patients in Asia, Latin America, and the Australia-New Zealand. The data was part of the session “Prevalence and…

Opicinumab, an investigative treatment aiming to promote remyelination in relapsing multiple sclerosis (MS) patients, will be tested in a new clinical trial —  having failed at an earlier effort, but having shown promise enough in particular patients to be worth a closer look. In fact, the new AFFINITY study “is…

Atara Biotherapeutics has started a Phase 1 clinical trial to assess ATA188’s safety and potential to treat progressive or relapsing-remitting multiple sclerosis. ATA188 is the company’s next-generation T-cell immunotherapy. It targets Epstein-Barr virus antigens that play an important role in the development of MS. An antigen is a molecule capable of…

An immune signaling protein called interleukin-35 has anti-inflammatory properties that scientists might harness to develop a therapy for multiple sclerosis and other autoimmune disorders, according to two studies. Researchers at the National Eye Institute of the National Institutes of Health discovered that a subunit of interleukin 35, which is also known as IL-35, significantly reduced inflammation in mouse models of eye inflammation and multiple sclerosis. Immune B-cells produce IL-35 to communicate with, and regulate the behavior of, surrounding cells. In a previous study, the research team found that the protein could inhibit inflammation in the eyes of animals with autoimmune uveitis, or inflammation of the inner layers of the eye. An autoimmune disease is one in which the immune system attacks healthy cells instead of invaders. A drawback of trying to use a synthetic version of IL-35 as a therapy is that it's difficult to produce because of its complex structure and it's unstable in a solution. Natural IL-35 is composed of two subunits, IL-12p35 and Ebi3, which bind to create the full protein. The team wondered if they could use a subunit, instead of the full protein, as an anti-inflammatory agent. Their study, “IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease,” was published in the journal Nature Communications, They demonstrated that the IL-12p35 subunit could generate anti-inflammatory effects similar to those of the full IL-35 protein. Giving IL-12p35 to mice with uveitis promoted the expansion of immune B-cells that counteract autoimmune responses, reversing the animals' eye symptoms. In the second study, researchers discovered that the subunit tempered inflammation in a mouse model of multiple sclerosis. Giving the animals IL-12p35 every other day for up to 12 days promoted immune cell proliferation that inhibited inflammation in the mice's brains and spinal cords, improving their symptoms. The research demonstrated IL-35 and its subunit's potential to treat nerve-inflammation disorders. The team published its findings in the journal Frontiers of Immunology. The article is titled “IL-12p35 inhibits neuroinflammation and ameliorates autoimmune encephalomyelitis.” The team is now looking at IL-12p35's ability to treat other degenerative eye diseases, such as diabetic retinopathy and macular degeneration.

In its work on multiple sclerosis (MS), Biogen has adopted a comprehensive approach that ranges from  drug development to the exploration of real-world data and digital markers of disease. The company will showcase these efforts at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris on October 25–28. Among its more than 80 presentations at the meeting are updates from its collaboration with Verily and Brigham and Women’s Hospital on using digital sensors that gather data on MS patients between physician visits. Biogen will also share data on the possibility of using such biomarkers to help neurologists in diagnosing and following MS patients — offering information that could potentially help them in making treatment decisions given the variability of the disease in MS patients. The company is also involved in a collaboration with 10 MS centers that aims to generate data collected during routine care. The MS PATHS study includes data from physical examinations, magnetic resonance imaging (MRI) scans, and biological samples. A third and similar project — the Big Multiple Sclerosis Data (BMSD) Network —  is merging data from five MS registries, holding prospective information on nearly 140,000 patients. Taken together, these large collections of high-quality, real-world data will help researchers better understand the disease, and so, increase the potential of new treatment discoveries, Biogen says. The company is also working to discover and develop biomarkers that are not digital that may also advance the understanding of MS and its treatment. One such marker is neurofilament light, which signals damage to neuronal axons. Biogen will share data on how this marker changes over time in MS patients. Among presentations focusing on treatment development, Biogen will highlight new efforts with opicinumab . The treatment — intended to repair damage by triggering remyelination — failed to reach it primary goal in the Phase 2 SYNERGY trial earlier this year. Still,  data indicated that some trial participants did respond to the treatment. At ECTRIMS, Biogen will present an analysis of the SYNERGY data that identifies factors — including specific MRI features — that may be linked to a treatment response.  

New data on how Lemtrada and Aubagio perform in a real-world setting will be the focus of Sanofi Genzyme when the company showcases its research at the upcoming 7th Joint ECTRIMS-ACTRIMS Meeting in Paris this week. Researchers will also share information about the safety of a new investigational therapy, GLD52 (GZ402668), currently in a Phase 1 safety study. The TOPAZ study is one of the main data sources for the upcoming presentations. The study, which follows relapsing MS patients who participated in the CARE MS-I and CARE MS-II extension study , is a rich source of information on long-term outcomes. Researchers will share various aspects of disease outcomes and magnetic resonance imaging (MRI) data from patients followed up to seven years, with some presentations focusing solely on those who switched from treatment with interferon beta-1a. Among the Lemtrada highlights are findings demonstrating that Lemtrada does not appear to trigger birth defects. Another presentation compared Lemtrada to Genentech’s Ocrevus using a model that evaluated both the cost and effectiveness of the two drugs. The analysis suggests that Lemtrada more effectively treated relapsing MS and was also linked to lower costs over a 20-year period. Aubagio studies also focused on long-term patient data, including in people with progressive forms of relapsing MS. Data from the Phase 3 TEMSO , TOWER , and the TEMSO extension showed that Aubagio stabilized disability progression in these patients over nearly a decade. Other presentations homed in on Aubagio’s ability to slow brain tissue loss and improve cognitive outcomes. Finally, Sanofi Genzyme shared initial data on its investigational antibody GLD52. The treatment is an updated form of Lemtrada, which scientists believe gives rise to fewer and milder infusion-related reactions. Data from the Phase 1 study , so far indicated that this might indeed be the case, as no severe reactions occurred in the 44 progressive MS patients in the trial. For a complete list of Sanofi Genzyme's presentations at the meeting, visit this link.